inhibitor
aminopeptidas
n
apn
thought
potenti
drug
treatment
tumor
angiogenesi
invas
metastasi
consider
number
apn
inhibitor
report
recent
clarifi
essenti
structureact
relationship
apn
inhibitor
well
identifi
new
potent
lead
apn
pharmacophor
model
establish
use
structureand
common
featurebas
approach
valid
databas
activ
inact
compound
valid
pharmacophor
use
databas
screen
novel
virtual
lead
hit
compound
subject
molecular
dock
studi
refin
retriev
hit
final
six
structur
divers
compound
show
strong
interact
key
amino
acid
zinc
ion
select
biolog
evalu
two
hit
show
inhibit
apn
concentr
evalu
result
show
potenti
screen
approach
identifi
apn
inhibitor
aminopeptidas
n
apn
zincdepend
type
ii
membranebond
ectopeptidas
wide
express
hematopoiet
cell
myeloid
origin
nonhematopoiet
cell
tissu
fibroblast
brain
cell
epitheli
cell
liver
kidney
intestin
vivo
apn
involv
metabol
angiotensin
iii
degrad
nociceptin
brain
peripher
organ
inactiv
enkephalin
associ
neutral
endopeptidas
nep
moreov
enzym
prove
behav
receptor
coronavirus
tgev
human
pig
ident
human
lymphocyt
surfac
cluster
differenti
antigen
apn
also
report
play
vital
role
invas
metastat
tumor
vitro
find
make
apn
import
target
therapeut
applic
requir
develop
select
potent
inhibitor
sinc
first
market
antiapn
drug
bestatin
launch
apn
inhibitor
probestin
lapstatin
ahpav
display
effici
inhibitori
abil
report
bestatin
amastatin
extens
studi
howev
recent
clinic
use
apn
inhibitor
limit
due
low
select
import
drug
resist
though
mani
differ
apn
inhibitor
synthes
experiment
assess
inform
avail
regard
discoveri
structur
novel
lead
date
thu
import
develop
new
small
molecul
inhibitor
novel
mode
action
develop
kind
drug
focus
design
novel
apn
inhibitor
chemic
featurebas
pharmacophor
virtual
librari
screen
may
serv
guid
design
novel
lead
candid
studi
aim
construct
chemic
featurebas
pharmacophor
model
identifi
novel
scaffold
potenti
turn
new
categori
apn
inhibitor
studi
success
use
pharmacophor
model
databas
screen
molecular
dock
approach
identifi
lead
candid
potent
inhibitori
activ
pharmacophor
model
gener
structureand
common
featurebas
approach
pharmacophor
model
valid
databas
activ
inact
compound
use
structur
search
queri
find
new
potent
lead
databas
bind
free
energi
molecular
interact
activ
site
residu
consid
import
compon
identifi
potenti
lead
highresolut
crystal
structur
human
aminopeptidas
n
chosen
gener
structurebas
pharmacophor
model
determin
import
pharmacophor
featur
ligand
bind
bind
site
analysi
tool
avail
discoveri
studio
ds
accelri
inc
san
diego
ca
usa
version
accelri
san
diego
usa
use
creat
sphere
radiu
compris
catalyt
import
amino
acid
residu
ligandbind
pocket
interact
gener
protocol
implement
ds
use
identifi
hydrogen
bond
acceptor
hba
hydrogen
bond
donor
hbd
hydrophob
hy
ring
aromat
ra
featur
base
activ
site
residu
insid
sphere
featur
cluster
repres
featur
select
includ
pharmacophor
model
pharmacophorea
select
suitabl
train
set
essenti
qualiti
automat
gener
pharmacophor
model
set
structur
divers
aminopeptidasen
inhibitor
select
literatur
train
set
establish
common
featurebas
pharmacophor
chemic
structur
select
molecul
draw
manual
use
chemdraw
cambridgesoft
cambridg
subsequ
export
ds
compound
minim
closest
local
minimum
base
charmmlik
forc
field
ds
hiphop
modul
avail
ds
employ
establish
pharmacophor
calcul
setup
two
ligand
properti
specifi
first
properti
princip
valu
defin
activ
level
molecul
princip
valu
indic
chemic
featur
refer
compound
consid
build
pharmacophor
space
model
gener
second
ligand
properti
defin
maxomitfeat
valu
specifi
mani
featur
allow
miss
compound
maxomitfeat
valu
allow
one
featur
gener
pharmacophor
must
map
molecul
compound
assign
princip
valu
maxomitfeat
valu
respect
compound
given
princip
maxomitfeat
valu
basi
analysi
chemic
featur
present
train
set
structur
hydrogen
bond
donor
hydrogen
bond
acceptor
hydrophob
featur
select
studi
maximum
number
energi
threshold
kcalmol
energi
minimum
conform
search
set
compound
use
best
conform
gener
option
among
possibl
hypothes
return
top
rank
hypothesi
pharmacophoreb
select
valid
gh
score
method
extern
databas
contain
compound
structur
differ
train
set
molecul
compound
databas
use
test
set
valid
discrimin
abil
best
pharmacophor
model
distinguish
activ
compound
inact
one
queri
perform
use
ligand
pharmacophor
map
protocol
gh
score
method
appli
quantifi
model
select
precis
hit
recal
activ
dataset
contain
known
activ
inact
method
includ
percent
ratio
activ
hit
list
precis
percent
yield
activ
databas
recal
gh
score
enrich
factor
e
high
e
valu
great
abil
pharmacophor
identifi
activ
compound
gh
test
score
rang
score
close
indic
ideal
model
follow
propos
metric
analyz
hit
list
pharmacophor
modelbas
databas
search
number
activ
compound
databas
number
compound
databas
ha
number
activ
hit
list
true
posit
ht
number
hit
retriev
percentag
known
activ
hit
list
recal
percentag
known
activ
compound
retriev
databas
precis
gh
score
e
enrich
concentr
activ
model
rel
random
screen
without
pharmacophor
approach
identifi
novel
hit
compound
valid
pharmacophor
model
use
queri
screen
inhous
databas
compound
ligand
pharmacophor
map
protocol
appli
databas
screen
final
retriev
compound
select
base
fit
valu
higher
bind
free
energi
molecular
interact
key
amino
acid
activ
site
molecular
oper
environ
moe
program
version
chemic
comput
group
inc
montreal
quebec
canada
use
perform
molecular
dock
calcul
dock
compound
built
use
moe
builder
interfac
subject
energi
minim
partial
charg
comput
use
forc
field
crystal
structur
apn
pdb
id
prepar
dock
studi
hydrogen
atom
ad
structur
standard
geometri
ii
partial
charg
comput
use
forc
field
activ
site
defin
radiu
around
bound
inhibitor
bestatin
crystal
structur
apn
molecular
dock
calcul
done
use
triangl
matcher
placement
method
london
dg
score
base
bind
mode
molecular
interact
observ
activ
site
final
hit
select
ic
valu
apn
determin
use
lleupnitroanilid
substrat
microsom
aminopeptidas
porcin
kidney
microsom
enzym
mm
pb
ph
ad
detect
compound
solut
variou
concentr
incub
apn
min
solut
substrat
ad
mixtur
incub
anoth
min
hydrolysi
substrat
measur
follow
chang
absorb
monitor
nm
plate
reader
varioskan
thermo
usa
workflow
overview
studi
includ
pharmacophor
model
select
compound
biolog
test
provid
fig
present
work
final
cluster
pharmacophor
pharmacophorea
gener
use
structurebas
model
approach
pharmacophor
model
basic
compos
one
hydrogenbond
acceptor
hba
two
hydrogenbond
donor
hbd
featur
space
distanc
constraint
featur
shown
fig
includ
addit
inform
size
shape
bestatinbind
pocket
apn
shape
constraint
ad
chemic
featur
pharmacophor
display
fig
carbonyl
group
bestatin
form
import
interact
zinc
ion
bind
site
apn
overlaid
hba
featur
pharmacophorea
addit
hydroxyl
group
molecul
show
ionic
interact
zinc
ion
map
one
hbd
featur
amino
group
enabl
consider
interact
water
molecul
map
hbd
featur
result
indic
fairli
good
map
bestatin
pharmacophorea
shape
constraint
howev
also
impli
pharmacophorea
may
util
screen
compound
chemic
structur
function
group
close
relat
bestatin
thu
qualit
pharmacophor
model
common
featurebas
model
hiphop
algorithm
necessari
identifi
structur
novel
lead
differ
bestatin
qualit
pharmacophor
model
apn
inhibitor
develop
use
hiphop
algorithm
ds
base
principl
structur
divers
seven
repres
apn
inhibitor
fig
select
use
train
set
common
featur
pharmacophor
model
studi
hydroxyl
carbonyl
group
metal
zinc
ion
bind
region
long
hydrophob
spacer
bind
hydrophob
residu
bestatinbind
site
apn
ten
common
featur
pharmacophor
model
gener
use
train
set
similar
number
pharmacophor
featur
five
featur
tabl
yet
variou
orient
vector
direct
top
rank
pharmacophor
pharmacophoreb
three
hydrogenbond
acceptor
hba
two
hydrophob
hy
featur
chosen
best
pharmacophor
model
fig
intern
databas
includ
compound
use
valid
process
databas
creat
inact
compound
inhibitor
known
experiment
activ
valid
abil
distinguish
activ
inact
compound
two
pharmacophor
b
use
queri
screen
intern
databas
use
ligand
pharmacophor
map
protocol
ds
set
statist
paramet
total
hit
ht
ratio
activ
yield
activ
enrich
factor
e
fals
neg
fals
posit
good
hit
score
gh
calcul
tabl
map
activ
molecul
screen
compound
databas
e
valu
pharmacophoreb
retriev
activ
compound
among
screen
molecul
total
compound
higher
e
valu
greater
abil
pharmacophor
identifi
activ
compound
valid
result
show
pharmacophor
model
b
effici
databas
screen
gh
score
higher
model
good
observ
pharmacophor
b
indic
good
abil
distinguish
activ
compound
inact
one
two
valid
pharmacophor
model
use
queri
screen
inhous
databas
consist
compound
result
molecul
select
screen
model
b
reduc
number
fals
posit
fals
neg
retriev
compound
fit
valu
higher
subject
dock
studi
molecular
dock
studi
could
provid
insight
understand
proteinligand
interact
structur
featur
activ
site
protein
begin
dock
necessari
valid
dock
reliabl
ligand
bestatin
crystal
structur
apnbestatin
complex
pdb
id
adopt
templat
perform
valid
ligand
bestatin
flexibl
redock
bind
site
apn
dock
conform
correspond
lowest
energi
score
select
probabl
bind
conform
result
redock
bestatin
almost
posit
activ
site
crystal
apn
complex
suggest
high
dock
reliabl
triangl
matcher
placement
method
london
dg
score
fig
therefor
dock
protocol
could
extend
search
bind
conform
retriev
hit
databas
refin
retriev
hit
also
remov
fals
posit
retriev
compound
dock
bestatinbind
site
apn
use
valid
dock
paramet
upon
visual
inspect
top
rank
compound
six
hit
show
key
interact
zinc
ion
select
biolog
valid
valid
reliabl
two
gener
pharmacophor
hypothes
hit
hit
test
vitro
inhibit
activ
apn
biolog
activ
test
result
report
inhibit
shown
tabl
hit
select
pharmacophoreb
fig
exhibit
inhibit
tabl
hit
select
biolog
valid
dock
score
fit
valu
apn
inhibit
concentr
apn
hit
select
pharmacophorea
fig
inhibit
apn
none
hit
select
pharmacophorea
display
apn
inhibit
two
hit
retriev
pharmacophoreb
show
higher
activ
hit
retriev
pharmacophorea
base
data
pharmacophoreb
two
hydrophob
three
hydrogen
bond
acceptor
featur
chosen
good
repres
computergener
model
identifi
new
apn
inhibitor
shown
tabl
activ
profil
six
hit
correl
fit
valu
comput
hypothesi
dock
sore
activ
hit
found
high
dock
score
fit
valu
among
four
hit
identifi
pharmacophorea
hit
show
best
inhibit
rate
fit
valu
dock
score
similarli
hit
screen
pharmacophoreb
display
stronger
inhibit
higher
fit
valu
better
dock
score
kcalmol
hit
overal
virtual
experiment
data
demonstr
screen
approach
good
potenti
identifi
apn
inhibitor
studi
bind
mode
two
potent
hit
hit
apn
dock
bestatinbind
site
apn
interact
map
hit
activ
site
apn
repres
fig
phenyl
ring
hit
exhibit
stack
interact
nitrogen
oxygen
atom
form
import
interact
zinc
ion
water
molecul
activ
site
apn
addit
establish
hydrophob
interact
shown
fig
phosphin
acid
group
hit
display
vital
ionic
interact
zinc
ion
hydrogenbond
interact
water
molecul
two
nitrogen
atom
engag
hydrogenbond
interact
water
molecul
moreov
molecul
also
show
hydrophob
interact
understand
interact
apn
hit
would
help
ration
design
novel
potent
apn
inhibitor
activ
site
residu
repres
follow
polar
residu
light
purpl
hydrophob
residu
green
acid
residu
red
contour
ring
basic
residu
blue
contour
ring
green
blue
arrow
indic
hydrogen
bond
side
chain
backbon
atom
respect
stack
interact
repres
green
dot
line
lightblu
halo
around
residu
indic
degre
interact
ligand
atom
larger
darker
halo
mean
interact
interpret
refer
color
figur
legend
reader
refer
web
version
articl
present
work
two
pharmacophor
model
b
develop
use
structureand
common
featurebas
approach
pharmacophor
model
provid
first
insight
hypothet
ligand
bind
requir
apn
inhibitor
valid
result
vitro
enzymat
inhibit
apn
impli
pharmacophoreb
compos
five
featur
better
pharmacophorea
identifi
potent
apn
inhibitor
inhibit
rate
hit
correl
fit
valu
comput
hypothesi
dock
score
possibl
search
commerci
databas
may
result
identif
potenti
activ
apn
inhibitor
shift
hit
obtain
virtual
screen
vivo
studi
outcom
report
near
futur
